Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

PURPOSE: To determine the maximum-tolerated dose (MTD) and assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of YM155, a small-molecule inhibitor of survivin. PATIENTS AND METHODS: Patients with advanced solid malignancies or lymphoma were treated with escalating do...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Tolcher, Anthony W., Mita, Alain, Lewis, Lionel D., Garrett, Christopher R., Till, Elizabeth, Daud, Adil I., Patnaik, Amita, Papadopoulos, Kyri, Takimoto, Chris, Bartels, Pamela, Keating, Anne, Antonia, Scott
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2008
Témata:
Phase I and Clinical Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879696/
https://ncbi.nlm.nih.gov/pubmed/18824702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.2064
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky